Mode
Text Size
Log in / Sign up

Vasopressin, steroids, and epinephrine triple therapy improves ROSC in in-hospital cardiac arrestTriple Therapy Shows Promise in Improving Cardiac Arrest Outcomes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that VSE triple therapy improves ROSC but shows low certainty for improving survival or neurological outcomes.

This meta-analysis evaluates the efficacy of a triple therapy consisting of vasopressin, steroids, and epinephrine (VSE) in patients experiencing in-hospital cardiac arrest. The analysis included a pooled assessment of 3 randomized trials and a network meta-analysis involving 21,768 patients to evaluate outcomes including return of spontaneous circulation (ROSC), survival, neurological status, and hemodynamic parameters.

The study found that VSE triple therapy provided a benefit for ROSC in the pooled analysis. In the network meta-analysis, VSE ranked above all comparators regarding hemodynamic outcomes. Additionally, an individual patient data reanalysis identified an independent protective effect of the corticosteroid component against post-resuscitation septic shock. However, the certainty of benefit for survival and neurological outcomes was low in the pooled analysis and remained unresolved in the network meta-analysis.

Several limitations were noted, including insufficient statistical power for hard endpoints, protocol differences between trials, and pharmacological limitations regarding glucocorticoids' access to neuroinflammation. While VSE shows promise for ROSC and hemodynamic stability, current 2025 AHA, ERC, and ILCOR guidelines do not recommend routine VSE during in-hospital cardiac arrest.

How this fits prior evidence

This meta-analysis addresses a gap in the management of in-hospital cardiac arrest by evaluating triple therapy. While standard cardiopulmonary resuscitation may improve survival rates following out-of-hospital cardiac arrest, this study specifically examines the addition of vasopressin and steroids to epinephrine. The finding of an independent protective effect of corticosteroids against septic shock adds specific nuance to the role of steroids in resuscitation.

Researchers looked at how a combination of three medications—vasopressin, steroids, and epinephrine—affects patients during in-hospital cardiac arrest. This analysis combined data from several trials involving thousands of patients to see if this triple therapy helped them recover.

The study found that the triple therapy was linked to a better return of spontaneous circulation. Additionally, one part of the treatment, the corticosteroid, showed an independent protective effect against septic shock after resuscitation. However, the evidence for long-term survival and neurological recovery remains uncertain or unclear in larger data sets.

Because of differences in how trials were run and limited data on some outcomes, these results are not yet enough to change standard medical guidelines. Doctors currently do not recommend this triple therapy as a routine treatment. Patients should talk to their medical team about specific treatments for cardiac events.

What this means for you:
Triple therapy shows a link to better circulation after cardiac arrest, but evidence for long-term recovery is limited.

Common questions

What is the triple therapy used for?

The triple therapy consists of three medications: vasopressin, steroids (corticosteroids), and epinephrine. It was studied to see if it could improve outcomes like circulation and survival for patients experiencing in-hospital cardiac arrest.

Does this treatment help with long-term recovery?

While the triple therapy showed a link to better circulation, the evidence for long-term survival and neurological outcomes is currently considered low or uncertain. More research is needed to confirm if it improves long-term recovery.

Is this treatment recommended by medical guidelines?

No, current 2025 guidelines from major heart associations do not recommend using the triple therapy as a routine treatment for in-hospital cardiac arrest. You should always consult with a healthcare professional regarding specific treatments.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
In-hospital cardiac arrest carries a hospital discharge survival rate of 22.6% in high-income settings, a figure unchanged over the past decade. Epinephrine reliably promotes return of spontaneous circulation (ROSC) but does not consistently improve neurologically intact survival. This limitation motivated the development of the vasopressin, steroids, and epinephrine (VSE) combination. This review examines the pharmacological rationale underpinning VSE and evaluates the clinical evidence across randomised trials, individual participant data analyses, and network meta-analyses. Vasopressin contributes V1a receptor-mediated vasoconstriction independent of adrenergic receptor status. Intra-arrest methylprednisolone enhances vascular reactivity and attenuates post-ROSC vasopressor requirements. Post-resuscitation hydrocortisone targets critical illness-related corticosteroid insufficiency, constituting a two-phase steroid strategy that defines the full Mentzelopoulos protocol. Pooled analysis of three randomised trials enrolling 869 patients assigns moderate certainty to the ROSC benefit and low certainty to survival and neurological outcome endpoints. A network meta-analysis of 36 trials enrolling 21,768 patients ranked VSE above all comparators for haemodynamic outcomes while leaving neurological endpoints unresolved. Individual patient data reanalysis identifies an independent protective effect of the corticosteroid component against post-resuscitation septic shock. The dissociation between ROSC and neurological recovery reflects insufficient statistical power for hard endpoints, protocol differences between trials, compartmentalised neuroinflammation only partially accessible to circulating glucocorticoids, and epinephrine-mediated cerebral microcirculatory impairment. The 2025 American Heart Association, European Resuscitation Council, and International Liaison Committee on Resuscitation guidelines do not recommend routine VSE during in-hospital cardiac arrest. Adequately powered trial evidence on patient-centred outcomes remains pending. Patient phenotype stratification and factorial trial design represent the most promising directions for future investigation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.